BR112013019080A2 - métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura - Google Patents

métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura

Info

Publication number
BR112013019080A2
BR112013019080A2 BR112013019080A BR112013019080A BR112013019080A2 BR 112013019080 A2 BR112013019080 A2 BR 112013019080A2 BR 112013019080 A BR112013019080 A BR 112013019080A BR 112013019080 A BR112013019080 A BR 112013019080A BR 112013019080 A2 BR112013019080 A2 BR 112013019080A2
Authority
BR
Brazil
Prior art keywords
nsclc
article
manufacture
methods
cancer
Prior art date
Application number
BR112013019080A
Other languages
English (en)
Inventor
s chen Daniel
Naumovski Louie
Hegde Priti
Funke Roel
bai Shuang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112013019080A2 publication Critical patent/BR112013019080A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura a invenção diz respeito à dosagem de anticorpos anti-egfl7 para a terapia do câncer.
BR112013019080A 2011-02-02 2012-02-01 métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura BR112013019080A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161438944P 2011-02-02 2011-02-02
US201161492743P 2011-06-02 2011-06-02
US201261587382P 2012-01-17 2012-01-17
PCT/US2012/023547 WO2012106473A2 (en) 2011-02-02 2012-02-01 Dosing for treatment with anti-egfl7 antibodies

Publications (1)

Publication Number Publication Date
BR112013019080A2 true BR112013019080A2 (pt) 2019-06-11

Family

ID=46603300

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013019080A BR112013019080A2 (pt) 2011-02-02 2012-02-01 métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura

Country Status (11)

Country Link
US (1) US20130004498A1 (pt)
EP (1) EP2670437A2 (pt)
JP (1) JP2014510044A (pt)
KR (1) KR20140012080A (pt)
CN (1) CN103476430A (pt)
AR (1) AR085105A1 (pt)
BR (1) BR112013019080A2 (pt)
CA (1) CA2825969A1 (pt)
MX (1) MX2013008922A (pt)
RU (1) RU2013140471A (pt)
WO (1) WO2012106473A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6195384B2 (ja) 2011-09-02 2017-09-13 シンダックス ファーマシューティカルズ，インク． 乳癌の処置方法
JP6584387B2 (ja) * 2013-05-17 2019-10-02 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 調節性ｔ細胞及びその使用
US11702469B2 (en) 2017-04-24 2023-07-18 Ohio State Innovation Foundation Recombinant EGFL7, EGFL7 antibodies, and uses thereof
US20190167790A1 (en) * 2017-12-05 2019-06-06 Abbvie Biotherapeutics Inc. Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059851A1 (es) * 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
PE20120902A1 (es) * 2009-05-08 2012-08-08 Genentech Inc Anticuerpos anti-egfl7 humanizados

Also Published As

Publication number Publication date
WO2012106473A8 (en) 2013-06-06
KR20140012080A (ko) 2014-01-29
MX2013008922A (es) 2013-10-01
CA2825969A1 (en) 2012-08-09
AR085105A1 (es) 2013-09-11
JP2014510044A (ja) 2014-04-24
CN103476430A (zh) 2013-12-25
RU2013140471A (ru) 2015-03-10
US20130004498A1 (en) 2013-01-03
WO2012106473A3 (en) 2012-11-01
EP2670437A2 (en) 2013-12-11
WO2012106473A2 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
AU2018256508A1 (en) Individualized vaccines for cancer
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
DK2766040T3 (da) Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
DK2750683T4 (da) Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
BR112014015003A2 (pt) composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
BR112014006419A2 (pt) métodos para tratar um paciente com câncer, kit e artigo
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
EA201201474A1 (ru) Способы лечения рака молочной железы
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
BR112015010220A2 (pt) métodos de utilização de biomarcadores para tratamento de câncer
BR112017025533A2 (pt) método para tratar câncer em um paciente humano
CY1121749T1 (el) Προφαρμακα ανταγωνιστων nmda
BR112013019080A2 (pt) métodos para o tratamento do câncer, do nsclc e do câncer colorretal em um paciente humano e artigo de manufatura
PH12017500923A1 (en) New dosage and use of a a2a antagonist
PH12015502516A1 (en) Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment
BR112012008316A2 (pt) utilização da assinatura microambiente sparc no tratamento de câncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]